Attention Deficit Hyperactivity Disorder, Behavior Disorders, Behavior Hyperactive
Conditions
Keywords
Attention Deficit Disorder with Hyperactivity, Addictive disorders, Neuropsychology, Methylphenidate, Atomoxetine, Functional impairment, Symptoms
Brief summary
The ADA cohort aims for the systematic and standardized collection of sociodemographic, clinical and neuropsychological data, during 2 visits (inclusion and 12 months), from patients suffering from the co-occurrence of ADHD (Attention Deficit Hyperactivity Disorder) and addiction(s), in addition to the treatment as usual adapted to each situation.
Detailed description
Information on the study and diagnosis of ADHD will be carried out during a medical evaluation consultation, as part of routine care. The two research visits (inclusion and at 12 months) will be added by the research and will each include: * A structured clinical interview with a research professional (traceability of oral consent, administration of structured interviews, collection of self-questionnaires, collection of care from the medical record) * A neuropsychological assessment with a neuropsychologist
Interventions
OTHERPatients suffering from the co-occurrence of ADHD and addiction(s)
All eligible patients over 18 years, presenting both a diagnosis of ADHD and a diagnosis of at least one addictive disorder (SUD, AUD (Alcohol Use Disorder) and/ or behavioral addiction), starting care in one of the three participating centers, and meeting the indication for treatment with MPH according to European recommendations (J. J. S. Kooij et al., 2019)
Sponsors
Nantes University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
Cohort
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
: * Patients aged over 18 years * For whom a diagnosis of ADHD has been confirmed less than 12 weeks ago * For whom the diagnosis of one or more addictive disorder(s) (substance use disorder or behavioral addiction) has been confirmed * Meeting the indication for treatment with MPH according to European recommendations (Kooij et al., 2019) * For patients who can actually benefit from MPH: who have not yet started taking MPH * Social security affiliates
Exclusion criteria
: * Presenting disorders of higher cognitive functions (at the discretion of the referring clinician or the investigator making the inclusion), making data collection impossible * Presenting difficulties in reading or writing the French language making data collection impossible * Unable to commit to being available for the 2 visits planned as part of the cohort * Under guardianship or legal protection * Patients who have used psychoactive substances within 12 hours prior to their visit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Functional impairment | Inclusion and 12-month follow-up | Weiss Functional Impairment Rating Scale (WFIRS-S) (scores of the 7 domains and total score) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Type and severity of ADHD | Inclusion | Diagnostiscal Interview Voor Attention deficit hyperactivity disorder (DIVA-5) |
| Symptoms of ADHD | Inclusion and 12-month follow-up | Adult ADHD Self-Report Scale Symptom Checklist (ASRS-1.1) (inattention and hyperactivity/impulsivity scores) |
| Addictive disorders - substance use disorders (including tobacco, alcohol and other substances) | Inclusion and 12-month follow-up | Mini International Neuropsychiatric Interview- Simplified for Diagnostic and Statistical Manual (DSM)-5 (MINI-S) |
| Addictive disorders - gambling disorder | Inclusion and 12-month follow-up | National Opinion research center DSM Screen for gambling problems (NODS) |
| Addictive disorders - sex addiction | Inclusion and 12-month follow-up | Structured interview adapted from the NODS to explore the diagnostic criteria proposed by Carnes et al in 2012 |
| Addictive disorders - eating addiction | Inclusion and 12-month follow-up | Yale Food Addiction Scale (YFAS 2.0) |
| Psychiatric disorders | Inclusion and 12-month follow-up | MINI-S |
| Neuropsychological profile - selective attention | Inclusion and 12-month follow-up | D2-R test (CCT standard score, E% standard score and CC standard score) |
| Neuropsychological profile - short-term and working memory | Inclusion and 12-month follow-up | Digit memory test (standardized scores of numbers of items correctly recalled (direct order, indirect order, ascending order, total), span sizes (direct order, indirect order, ascending order)) |
| Neuropsychological profile - inhibition | Inclusion and 12-month follow-up | Stroop test (standardized execution times (naming condition, interference condition), standardized numbers of uncorrected errors (naming condition, interference condition), and standardized interference score) |
| Neuropsychological profile - spontaneous flexibility | Inclusion and 12-month follow-up | Verbal fluency test (standardized scores for the number of words cited and the number of errors, in both conditions (literal and categorical)) |
| Neuropsychological profile - planning | Inclusion and 12-month follow-up | Zoo test (total profile score) |
| Psychopathological profile - impulsivity | Inclusion and 12-month follow-up | Urgency, Premeditation (lack of), Perseverance (lack of), Sensation seeking impulsivity behavior scale (UPPS-P) (5 scores) |
| Psychopathological profile - emotional dysregulation | Inclusion and 12-month follow-up | Difficulties in Emotion Regulation Scale (DERS-16) (5 scores and total score) |
| Psychopathological profile - sensorial profile | Inclusion and 12-month follow-up | Sensory profile of Winnie Dunn - adult version (category and raw scores in the 4 quadrants) |
| Psychopathological profile - self-esteem | Inclusion and 12-month follow-up | Rosenberg Self-Esteem Scale (RSES) (total score) |
| Quality of life survey | Inclusion and 12-month follow-up | World Health Organization Quality Of Life (WHOQoL-26) (4 scores) |
| Care received | 12-month follow-up | Effective implementation of treatment with MPH (yes/no) or atomoxetine (yes/no), If no, reasons for not implementing it (for MPH), Care provided (Cognitive remediation / behavioral and cognitive therapy / psychoeducation / other psychosocial intervention (details) / other drug treatment), Reported compliance and misuse for MPH and atomoxetine, Reported compliance for non-drug care, Tolerance: numerical scale from 0 to 10 for the evaluation of the main adverse effects (for MPH and for atomoxetine). |
| Personal and family medical history | Inclusion | List of somatic, psychiatric and addictive disorders for personal history, list of psychiatric and addictive disorders for family history |
| Sociodemographics | Inclusion | Age, gender, level of education, professional status, number of children |
Countries
France
Contacts
CONTACTClémence CABELGUEN, PH
Outcome results
None listed